# S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)

> **NCT04141670** · PHASE1 · COMPLETED · sponsor: **RyCarma Therapeutics, Inc.** · enrollment: 7 (actual)

## Conditions studied

- RYR-1 Myopathy

## Interventions

- **DRUG:** S48168

## Key facts

- **NCT ID:** NCT04141670
- **Lead sponsor:** RyCarma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141670, "S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04141670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*